Lung cancer: lower mortality risk after statins use
Lung cancer: lower mortality risk after statins use
1 May 2015Lung cancer patients who used statins in the year prior to a lung cancer diagnosis or after a lung cancer diagnosis had a reduction in the risk of death from the disease, a new study shows.
Clinical study design and results from 14.000 patients
Cardwell and colleagues used data from nearly 14,000 patients newly diagnosed with lung cancer between 1998 and 2009 from English cancer registry data. They gathered the patients' prescription records from the U.K. Clinical Practice Research Datalink and mortality data up to 2012 from the Office of National Statistics.
In general, a reduction in the risk of death from the disease was observed after analyzing the collected data. In particular, scientists reported that:
- Among patients who survived at least six months after a diagnosis, those who used statins after a lung cancer diagnosis had a statistically non-significant 11% reduction in lung cancer-specific deaths
- Among those who used at least 12 prescriptions of statins there was a statistically significant 19% reduction in lung cancer-specific deaths
- Among those who used lipophilic statins such as simvastatin there was a 19% reduction in lung cancer-specific deaths as well
- Among all patients in the study, those who used statins in the year before a lung cancer diagnosis had a statistically significant 12% reduction in lung cancer-specific deaths.
Chris Cardwell, PhD, a senior lecturer in medical statistics at the Centre for Public Health at Queen's University Belfast in Northern Ireland noted that the outcomes were not different between non-small cell lung cancer patients and small cell lung cancer patients in this study.
Relatively confounding results leading to further investigation
"Our study provides some evidence that lung cancer patients who used statins had a reduction in the risk of death from lung cancer," said C. Cardwell. "The magnitude of the association was relatively small and, as with all observational studies, there is the possibility of confounding -- meaning that simvastatin [a type of statin] users may have differed from simvastatin nonusers in other ways that could have protected them from death from cancer, for which we could not correct. However, this finding is worthy of further investigation in observational studies," Cardwell explained.
"If replicated in further observational studies, this would provide evidence in favor of conducting a randomized, controlled trial of simvastatin in lung cancer patients" Cardwell added.
"We hope to conduct a similar analysis in a large cohort of lung cancer patients from Northern Ireland," Cardwell added.
Source: Science Daily